Ventyx Biosciences, Inc. Overview
Pro stress-test →Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Lilly will acquire all outstanding shares at $14.00 per share in an all-cash transaction valued at approximately $1.2 billion, with the transaction expected to close in the first half of 2026.
Strategic Profile
Pro stress-test →The company's expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, with extensive experience in clinical development allowing rapid progression through clinical trials. Lead portfolio includes NLRP3 inhibitors VTX2735 and VTX3232 in Phase 2 development, plus inflammatory bowel disease candidates tamuzimod and VTX958 that have completed Phase 2 trials.
Competitive Landscape
Pro stress-test →Ventyx operates in clinical-stage biotech with 52 identified competitors including RedHill Biopharma. The company differentiates through oral NLRP3 inhibitors targeting inflammation-driven chronic diseases where limited treatment options exist. Acquisition by Lilly positions pipeline within a major pharma focused on inflammatory and cardiometabolic indications.
Industry Context
Ventyx Biosciences, Inc. operates in Biopharmaceuticals - Clinical-Stage Drug Development.
Key facts
Founded: 2018 · Headquarters: San Diego, United States · Market cap: $1.0B